Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia

S. R. Nussbaum, R. P. Warrell, R. Rude, J. Glusman, J. P. Bilezikian, A. F. Stewart, M. Stepanavage, J. F. Sacco, S. D. Averbuch, B. J. Gertz

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


Purpose: A randomized, double-blind, dose-ranging study of single-dose intravenous (IV) therapy with alendronate sodium (aminohydroxybutylidene bisphosphonate) was performed in patients with cancer-associated hypercalcemia. Patients and Methods: Patients with hypercalcemia who had not received antitumor therapy in the preceding 7 days were treated with 48 hours of IV hydration. Patients with persistent hypercalcemia (albumin-corrected serum calcium concentration [CSCC] ≥ 11.5 mg/dL) were randomly assigned to receive 2.5, 5, 10, or 15 mg of alendronate infused over 2 hours, or 10 mg of alendronate infused over 24 hours. Fifty-nine patients were treated and 50 patients were assessable for the dose-response relationship. Results: Normalization of CSCC (≤ 10.5 mg/dL) was achieved in 22%, 82%, 75%, and 90% of assessable patients in the 2.5-, 5-, 10- (2- and 24-hour groups pooled), and 15-mg dose groups, respectively, within 8 days of therapy. Doses ≥ 5 mg were significantly superior to the 2.5-mg dose level (P < .05). There was no significant difference in the minimum CSCC achieved between the 2- and 24-hour infusions of the 10-mg dose. Based on an intent-to-treat analysis of all randomized patients, the overall complete response rate was 74% for dose levels greater than 2.5 mg. For assessable patients who responded to ≥ 5 mg of alendronate, the estimated median duration of normocalcemia was 10 days (range, 1 to 25). The estimated median time to relapse (CSCC > 11.5 mg/dL) was 15 days from initial treatment and 12 days from initial response, respectively. Adverse events included a transient febrile response in 34% of patients and eight episodes of reversible elevations in serum transaminase levels among treated patients. Conclusion: While a statistically significant dose-response relationship was not clearly evident at doses greater than 5 mg, single doses of ≥ 5 mg alendronate sodium effectively lowered serum calcium concentrations and were well tolerated in the treatment of cancer-associated hypercalcemia.

Original languageEnglish
Pages (from-to)1618-1623
Number of pages6
JournalJournal of Clinical Oncology
Issue number8
StatePublished - 1993


Dive into the research topics of 'Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia'. Together they form a unique fingerprint.

Cite this